SLC5A2 and type 2 diabetes mellitus: Findings from the recent cardiovascular outcome trials have demonstrated that SGLT2 inhibitors reduced hospitalization for HF by 27–35% in patients with T2DM with or without CVD and with or without a history of HF (5–7).